Grimm EA - Search Results

1

Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.

Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Yang SC, et al. Among authors: grimm ea. Cancer Immunol Immunother. 1989;29(3):193-8. doi: 10.1007/BF00199995. Cancer Immunol Immunother. 1989. PMID: 2543502 Free PMC article.

2

Combination immunotherapy for advanced lung cancer.

Yang SC, Grimm EA, Roth JA. Yang SC, et al. Among authors: grimm ea. J Natl Cancer Inst Monogr. 1992;(13):197-201. J Natl Cancer Inst Monogr. 1992. PMID: 1327033 Clinical Trial.

3

IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin).

Lazenby AW, Roth JA, Owen-Schaub LB, Grimm EA. Lazenby AW, et al. Among authors: grimm ea. Cytokine. 1992 Nov;4(6):479-87. doi: 10.1016/1043-4666(92)90008-f. Cytokine. 1992. PMID: 1337985

4

DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.

Owen-Schaub LB, Yonehara S, Crump WL 3rd, Grimm EA. Owen-Schaub LB, et al. Among authors: grimm ea. Cell Immunol. 1992 Mar;140(1):197-205. doi: 10.1016/0008-8749(92)90187-t. Cell Immunol. 1992. PMID: 1371242

5

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.

Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA. Yang SC, et al. Among authors: grimm ea. Cancer Res. 1991 Jul 15;51(14):3669-76. Cancer Res. 1991. PMID: 1648441 Clinical Trial.

6

Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.

Yang SC, Fry KD, Grimm EA, Roth JA. Yang SC, et al. Among authors: grimm ea. J Immunother (1991). 1991 Oct;10(5):326-35. doi: 10.1097/00002371-199110000-00004. J Immunother (1991). 1991. PMID: 1790140

7

Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Grimm EA, Bruner JM, Carinhas J, Köppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP. Grimm EA, et al. Cancer Immunol Immunother. 1991;32(6):391-9. doi: 10.1007/BF01741334. Cancer Immunol Immunother. 1991. PMID: 1848799 Free PMC article.

8

The IL-2 mediated amplification of cellular cytotoxicity.

Grimm EA, Owen-Schaub L. Grimm EA, et al. J Cell Biochem. 1991 Apr;45(4):335-9. doi: 10.1002/jcb.240450405. J Cell Biochem. 1991. PMID: 2045426 Review.

9

IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes.

Owen-Schaub LB, de Mars M, Murphy EC Jr, Grimm EA. Owen-Schaub LB, et al. Among authors: grimm ea. Cell Immunol. 1991 Jan;132(1):193-200. doi: 10.1016/0008-8749(91)90018-7. Cell Immunol. 1991. PMID: 2065356

10

Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.

Yang SC, Fry KD, Grimm EA, Roth JA. Yang SC, et al. Among authors: grimm ea. Arch Surg. 1990 Feb;125(2):220-5. doi: 10.1001/archsurg.1990.01410140098016. Arch Surg. 1990. PMID: 2137327

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters